Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III: UbLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)

NCT03277248 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.

NCT NCT03277248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03277248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III: UbLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)
Lead sponsor
TG Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 25, 2017
Completion date
November 12, 2020
Enrollment
545 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis (rms)